Scholar Rock, a clinical-stage biopharma company focused on the treatment of diseases in which protein growth plays a large role, has named Jing Marantz, MD, PhD, as chief medical officer.
Most recently, Dr. Marantz served as the executive vice president and chief business officer at Krystal Biotech. Additionally, she currently serves on the board of Arcturus Therapeutics, according to a Nov. 9 Scholar Rock news release.
"I look forward to overseeing future clinical development, including the Phase 1 DRAGON proof-of-concept trial of SRK-181 in patients with advanced cancer, and progressing the Phase 3 SAPPHIRE trial of apitegromab for the treatment of SMA towards potential regulatory approval," Dr. Marantz said.